Key Takeaways
- • CVC Capital Partners has tabled a non-binding offer to acquire Italian pharmaceutical company Recordati for €10.9 billion ($12.6 billion), or €52.00 ($60) per share, with plans to delist the company from public markets.
- • CVC already owns a 47% controlling stake in Recordati following its 2018 investment of €3.03 billion ($3.5 billion) for a 51.8% stake, positioning it as the dominant shareholder in the family-run business.
- • The offer remains subject to multiple conditions including completion of due diligence, securing financing, and identifying additional partners, with no guarantee of deal completion.
- • Recordati has grown substantially over the past decade, more than doubling sales to €2.6 billion ($2.9 billion) in the prior year, driven partly by its 2021 acquisition of EUSA Pharma and rare-disease focus including the Cushing disease treatment Iturisa.
- • Market reaction was immediate, with Recordati's share price climbing 5% following the news announcement, reflecting investor perception of valuation opportunity.
Summary
CVC Capital Partners has made a formal offer to acquire Italian pharmaceutical manufacturer Recordati Industria Chimica e Farmaceutica SpA for €10.9 billion ($12.6 billion), valuing the company at €52.00 ($60) per share. Recordati confirmed the non-binding offer on March 27, 2026, following earlier reporting by Italian financial outlet Il Sole 24 Ore. The Luxembourg-based private equity firm, which currently holds a 47% stake in the company following its 2018 investment, intends to fully delist Recordati if the transaction proceeds.
The offer is expressly non-binding and contingent upon multiple conditions, including satisfactory completion of due diligence, CVC's ability to secure necessary financing, and the identification of additional partners to participate in the acquisition. Recordati's board stated it has not yet conducted a substantive review of the proposal. This structure provides both parties with flexibility while signaling serious intent from CVC to consolidate full ownership of the company.
Recordati's operational trajectory supports the valuation. The company, now in its 100th year of operation, has more than doubled sales over the past decade, reaching €2.6 billion ($2.9 billion) in annual revenues. The growth reflects strategic acquisitions, notably its 2021 purchase of EUSA Pharma for €750 million ($845 million), which brought the rare-disease treatment Iturisa into its portfolio. Recordati recently doubled its peak sales projection for Iturisa to €1.2 billion ($1.4 billion), signaling confidence in the asset's commercial potential within its rare-disease strategic focus.
Market participants reacted positively to the announcement, with Recordati's share price rising approximately 5% during intraday trading on the news disclosure. This movement reflects institutional recognition of the offer's valuation floor and CVC's demonstrated commitment to completing transactions within the pharmaceutical sector. The deal represents CVC's continued investment in specialty and rare-disease pharmaceuticals, aligning with broader industry consolidation trends in the sector.
The offer is expressly non-binding and contingent upon multiple conditions, including satisfactory completion of due diligence, CVC's ability to secure necessary financing, and the identification of additional partners to participate in the acquisition. Recordati's board stated it has not yet conducted a substantive review of the proposal. This structure provides both parties with flexibility while signaling serious intent from CVC to consolidate full ownership of the company.
Recordati's operational trajectory supports the valuation. The company, now in its 100th year of operation, has more than doubled sales over the past decade, reaching €2.6 billion ($2.9 billion) in annual revenues. The growth reflects strategic acquisitions, notably its 2021 purchase of EUSA Pharma for €750 million ($845 million), which brought the rare-disease treatment Iturisa into its portfolio. Recordati recently doubled its peak sales projection for Iturisa to €1.2 billion ($1.4 billion), signaling confidence in the asset's commercial potential within its rare-disease strategic focus.
Market participants reacted positively to the announcement, with Recordati's share price rising approximately 5% during intraday trading on the news disclosure. This movement reflects institutional recognition of the offer's valuation floor and CVC's demonstrated commitment to completing transactions within the pharmaceutical sector. The deal represents CVC's continued investment in specialty and rare-disease pharmaceuticals, aligning with broader industry consolidation trends in the sector.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.